Belimumab for the Treatment of Systemic Lupus Erythematosus: A Systematic Review

Abstract

Introduction: Systemic Lupus Erythematosus (SLE) is a complex autoimmune disease. Belimumab, a monoclonal antibody that inhibits B-lymphocyte stimulator (BLyS), was the first biologic approved for SLE. This review evaluates its efficacy and safety.

Methods: A search of MEDLINE and Embase was conducted for placebo-controlled RCTs of belimumab in patients with active, autoantibody-positive SLE receiving standard therapy. The primary outcome was the composite SLE Responder Index (SRI).

Results: The meta-analysis of four large RCTs demonstrated that a significantly higher proportion of patients treated with belimumab achieved an SRI response compared to placebo. Belimumab also reduced the risk of severe flares and allowed for a reduction in corticosteroid dosage. The safety profile was favorable.

Discussion: Belimumab provides a modest but consistent benefit as an add-on therapy in SLE. Its steroid-sparing effect is a key advantage. It is particularly effective in patients with high disease activity and musculoskeletal or mucocutaneous involvement.

Conclusion: Belimumab is an effective and safe adjunctive therapy for improving disease activity and reducing flares in patients with systemic lupus erythematosus.